AU2023286251A1 - Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis - Google Patents
Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis Download PDFInfo
- Publication number
- AU2023286251A1 AU2023286251A1 AU2023286251A AU2023286251A AU2023286251A1 AU 2023286251 A1 AU2023286251 A1 AU 2023286251A1 AU 2023286251 A AU2023286251 A AU 2023286251A AU 2023286251 A AU2023286251 A AU 2023286251A AU 2023286251 A1 AU2023286251 A1 AU 2023286251A1
- Authority
- AU
- Australia
- Prior art keywords
- hydrogen
- mmol
- tetrahydroquinolin
- reaction
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022101476 | 2022-06-24 | ||
| JP2022-101476 | 2022-06-24 | ||
| PCT/JP2023/023264 WO2023249106A1 (ja) | 2022-06-24 | 2023-06-23 | 筋萎縮性側索硬化症の治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023286251A1 true AU2023286251A1 (en) | 2024-12-05 |
Family
ID=89380133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023286251A Pending AU2023286251A1 (en) | 2022-06-24 | 2023-06-23 | Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260083723A1 (https=) |
| EP (1) | EP4545079A1 (https=) |
| JP (1) | JPWO2023249106A1 (https=) |
| KR (1) | KR20250026152A (https=) |
| CN (1) | CN119403554A (https=) |
| AU (1) | AU2023286251A1 (https=) |
| CA (1) | CA3256001A1 (https=) |
| WO (1) | WO2023249106A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801593A (en) | 1979-09-13 | 1989-01-31 | Burroughs Wellcome Co. | Chemotherapeutic agents |
| JP3209568B2 (ja) | 1991-04-16 | 2001-09-17 | 杏林製薬株式会社 | 新規環状アミノフェニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤 |
| KR100236910B1 (ko) | 1992-12-14 | 2000-04-01 | 김영환 | 고집적 반도체 기억소자의 메모리셀어레이 제조방법 |
| DE10236910A1 (de) | 2002-08-12 | 2004-03-11 | Grünenthal GmbH | Substituierte 1,2,3,4-Tetrahydrochinolinderivate |
| ATE507220T1 (de) | 2003-12-20 | 2011-05-15 | Merck Patent Gmbh | Tetrahydropyranochinolinderivate |
| DE102005027170A1 (de) | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| EP2733138B1 (en) * | 2011-07-15 | 2016-09-28 | Hamari Chemicals, Ltd. | Method for producing optically active tetrahydroquinoline |
| US20140228420A1 (en) | 2011-09-05 | 2014-08-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof |
| WO2019106434A1 (en) * | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
| CN113631535B (zh) * | 2019-03-11 | 2024-04-12 | 协同医药发展有限公司 | 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物 |
| CN110372614B (zh) | 2019-07-03 | 2020-09-29 | 山东师范大学 | 一种四氢喹喔啉类化合物及制备方法与应用 |
| CN110464727B (zh) | 2019-09-06 | 2025-09-23 | 山东师范大学 | 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用 |
| IL303307A (en) * | 2020-12-25 | 2023-07-01 | Toray Industries | Tetrahydroquinoline derivative and its medical use |
-
2023
- 2023-06-23 JP JP2023539099A patent/JPWO2023249106A1/ja active Pending
- 2023-06-23 CA CA3256001A patent/CA3256001A1/en active Pending
- 2023-06-23 EP EP23827288.4A patent/EP4545079A1/en active Pending
- 2023-06-23 US US18/877,122 patent/US20260083723A1/en active Pending
- 2023-06-23 AU AU2023286251A patent/AU2023286251A1/en active Pending
- 2023-06-23 WO PCT/JP2023/023264 patent/WO2023249106A1/ja not_active Ceased
- 2023-06-23 KR KR1020247034823A patent/KR20250026152A/ko active Pending
- 2023-06-23 CN CN202380048404.5A patent/CN119403554A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023249106A1 (ja) | 2023-12-28 |
| EP4545079A1 (en) | 2025-04-30 |
| US20260083723A1 (en) | 2026-03-26 |
| CN119403554A (zh) | 2025-02-07 |
| JPWO2023249106A1 (https=) | 2023-12-28 |
| CA3256001A1 (en) | 2025-03-18 |
| KR20250026152A (ko) | 2025-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799007B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설폰아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| US5696136A (en) | Method of treating psychosis using azaheterocyclylmethyl | |
| US8163766B2 (en) | Beta-secretase modulators and methods of use | |
| CA2763960C (en) | Bicyclic and tricyclic compounds as kat ii inhibitors | |
| JP2004518660A (ja) | ４−位においてピペラジン含有部分で置換されたキノリンおよびその窒素化誘導体ならびにその抗菌剤としての使用 | |
| JP2003502419A (ja) | 抗菌剤としてのキノリン誘導体 | |
| US12570639B2 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
| CN115210233B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| ES2277098T3 (es) | Derivados de quinolina y aza-indol y su uso como ligandos para 5-ht6. | |
| AU2010211583A1 (en) | Dihydroquinolinone derivatives | |
| JP2004517130A (ja) | 治療用クロマン化合物 | |
| EP2731932B1 (en) | Aminomethyl quinolone compounds | |
| KR102526281B1 (ko) | 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도 | |
| JP2017100951A (ja) | オキサゾリジノン及びオキサジナノン誘導体 | |
| WO2011061318A1 (en) | Heterocylic compounds as antagonists of the orexin receptors | |
| AU2023286251A1 (en) | Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis | |
| RU2850795C1 (ru) | Производное тетрагидрохинолина и его медицинское применение | |
| TWI917519B (zh) | 四氫喹啉衍生物及其醫藥用途 | |
| WO2023249105A1 (ja) | 薬剤性心筋障害の治療剤又は予防剤 | |
| TWI793010B (zh) | 具有alk抑制活性的化合物及其製備方法和用途 | |
| WO2023249107A1 (ja) | 末梢神経障害の治療剤又は予防剤 | |
| HK40096343A (zh) | 四氢喹啉衍生物及其医药用途 | |
| HK1192563A (en) | Aminomethyl quinolone compounds | |
| HK1192563B (en) | Aminomethyl quinolone compounds |